130312-10-6

Basic information

• Product Name: 4-(2-OXO-ETHYL)-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER
• Synonyms: N-CBZ-PIPERIDINYL-4-ACETALDEHYDE;4-(2-OXO-ETHYL)-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER;1-CBZ-4-(2-OXO-ETHYL)-PIPERIDINE;Benzyl 4-(2-oxoethyl)piperidine-1-carboxylate
• CAS NO: 130312-10-6
• Molecular Formula: C₁₅H₁₉NO₃
• Molecular Weight: 261.32
• Mol File: 130312-10-6.mol

Chemical Properties

• Boiling Point: 403.8±28.0 °C(Predicted)
• Appearance: /
• Density: 1.132±0.06 g/cm3(Predicted)
• PKA: -1.67±0.40(Predicted)
• CAS DataBase Reference: 4-(2-OXO-ETHYL)-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-OXO-ETHYL)-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER(130312-10-6)
• EPA Substance Registry System: 4-(2-OXO-ETHYL)-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER(130312-10-6)

Safety Data

• Hazardous Substances Data: 130312-10-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-OXO-ETHYL)-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER is used as a building block for the synthesis of various drugs and bioactive compounds, contributing to the development of new medications and therapies.
Used in Organic Synthesis:
In the field of organic synthesis, 4-(2-OXO-ETHYL)-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER is used as a protecting group, which is crucial for facilitating specific chemical reactions without unwanted side reactions, thus improving the yield and purity of the desired products.
Used in Chemical Intermediates Preparation:
4-(2-OXO-ETHYL)-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER is utilized as a precursor in the preparation of chemical intermediates, which are essential for the production of a wide range of chemical products, including pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Materials Science:
In materials science, 4-(2-OXO-ETHYL)-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER may find applications in the development of new materials with specific properties, such as improved biocompatibility or enhanced drug delivery capabilities, due to its unique chemical structure and reactivity.

Upstream product

• 79-37-8 oxalyl dichloride 
• 115909-91-6 1-(Benzyloxycarbonyl)-4-(2-hydroxyethyl)piperidine 
• 63845-29-4 benzyl 4-(2-chloro-2-oxoethyl)piperidine-1-carboxylate 
• 108-20-3 di-isopropyl ether 
• 622-26-4 4-(2-Hydroxyethyl)piperidine 
• 501-53-1 benzyl chloroformate 
• 82244-11-9 ethyl-1-carbobenzoxy-Δ^4,α-piperidine-4-acetate 
• 19099-93-5 benzyl 4-oxo-1-piperidinecarboxylate 

Downstream Products

• 1228588-83-7 C₁₈H₂₆N₂O₄ 
• 1322746-27-9 (E)-methyl 2-(tert-butyloxycarbonylamino)-4-(1-benzyloxycarbonylpiperidin-4-yl)but-2-enoate 
• 1322746-29-1 (S)-2-tert-butyloxycarbonylamino-4-(1-benzyloxycarbonylpiperidin-4-yl)butanoic acid 
• 1322746-32-6 (S)-2-tert-butyloxycarbonylamino-4-(1-(4-nitrobenzyloxy)carbonylpiperidin-4-yl)butanoic acid methyl ester 
• 1322746-28-0 (S)-2-tert-butyloxycarbonylamino-4-(1-benzyloxycarbonylpiperidin-4-yl)butanoic acid methyl ester 
• 1570178-35-6 1-{1-[(benzyloxy)carbonyl]piperidin-4-yl}propan-2-yl 5-(methylsulfonyl)-2,3-dihydro-1H-indole-1-carboxylate 
• 1242429-10-2 benzyl 4-(2-hydroxypropyl)piperidine-1-carboxylate 
• 1352733-74-4 benzyl 4-allylpiperidine-1-carboxylate 

Relevant articles and documents

ESTROGEN RECEPTOR DEGRADING PROTACS

The specification generally relates to compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4, R6, R7, R8, Linker, A, G, D and E have a

NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF

The present disclosure relates to novel compounds having estrogen receptor alpha degradation activity, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions.

TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS

The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, Inhibitors of Apoptosis Proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE

Provided herein are certain substituted N-aryl and N-heteroaryl piperidine compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, L, R4, L1, Q, R5 and R 6 are as defined. The said novel compounds, and pharmaceutically acceptable compositions comprising a compound thereof, may be useful as Liver X-β receptor(LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory disease and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE

Piperidine compounds of the Formular: (I) and pharmaceutically acceptable salts thereof, wherein X, Y, R 1, R 2, R 3, L, R 4, L 1, Q and R 5 are as defined herein. The compounds and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE

Substituted aryl and heteroaryl ether compounds of the Formula (I) and pharmaceutically acceptable salts thereof, wherein X, R 1, R 2, R 3, L, R 4, L 1, Q, and R 5 are as defined herein. These compounds and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

Discovery of a novel series of indoline carbamate and indolinylpyrimidine derivatives as potent GPR119 agonists

GPR119 has emerged as an attractive target for anti-diabetic agents. We identified a structurally novel GPR119 agonist 22c that carries a 5-(methylsulfonyl)indoline motif as an early lead compound. To generate more potent compounds of this series, structural modifications were performed mainly to the central alkylene spacer. Installation of a carbonyl group and a methyl group on this spacer significantly enhanced agonistic activity, resulting in the identification of 2-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]propyl 7-fluoro-5-(methylsulfonyl)-2,3-dihydro-1H-indole-1-carboxylate (20). To further expand the chemical series of indoline-based GPR119 agonists, several heterocyclic core systems were introduced as surrogates of the carbamate spacer that mimic the presumed active conformation. This approach successfully produced an indolinylpyrimidine derivative 37, 5-(methylsulfonyl)-1-[6-({1-[3-(propan-2- yl)-1,2,4-oxadiazol-5-yl]piperidin-4-yl}oxy)pyrimidin-4-yl]-2, 3-dihydro-1H-indole, which has potent GPR119 agonist activity. In rat oral glucose tolerance tests, these two indoline-based compounds effectively lowered plasma glucose excursion and glucose-dependent insulin secretion after oral administration.

MODULATORS OF TOLL-LIKE RECEPTORS

Provided are modulators of TLRs of Formula II: pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

TRIAZOLO-1,4-DIAZEPINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS

A triazolo-1,4-di-azepine compound of the below given formulas and a pharmacologically acceptable salt thereof are disclosed and useful in the pharmaceutical field, especially to allergic diseases. STR1 in which R1 and R2 are hydrogen or an alkyl, R3 is hydrogen or a halogen, R4 is hydrogen or an alkyl, X is--OCO--,--NHCO--,--CO--or others and Y is a cycloalkyl, a cycloalkylalkyl, an alkynyl or others.

Antirhinoviral heteroamine-substituted pyridazines

Novel pyridazinamines having antirhinoviral activity, compositions containing these compounds as active ingredient, and a method of inhibiting combating or preventing the growth of viruses in warm-blooded animals suffering from diseases caused by these viruses.